Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: Dr Ingelman-Sundberg, Ms Sim, and Dr Nebert claim that our definition of the CYP1A2 alleles is incorrect because it is not in accordance with the Human Cytochrome P450 (CYP) Allele Nomenclature Committee's definition.1 The confusion over the naming stems from that committee's decision to change the name of the highly inducible allele from CYP1A2*1A, as described in the original publication by Sachse et al,2 to CYP1A2*1F. In that article, the highly inducible allele has the “A” nucleotide at position +734 (also referred to as position –163). We indicated in our article that we detected the A→C polymorphism described by the widely accepted dbSNP reference number (rs762551) on the National Center for Biotechnology Information (NCBI) Web site,3 and we defined the allele containing the “A” nucleotide as CYP1A2*1A. Despite the claims of Ingelman-Sundberg et al, recent studies4- 6 continue to define the highly inducible allele as CYP1A2*1A and the noninducible allele as CYP1A2*1F, consistent with our usage. The only unambiguous method of describing these alleles is to refer to “the nucleotide at position –163” rather than the CYP1A2*1A/*1F designation.
Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, Myocardial Infarction, and CYP Nomenclature—Reply. JAMA. 2006;296(7):764-766. doi:10.1001/jama.296.7.765